Beam Therapeutics Inc (NASDAQ:BEAM) shares are popping on Monday after the company laid out a series of pipeline updates and strategic priorities for 2026. Here’s what you should know.
Beam's FDA Progress Could Transform AATD Treatment
Beam has reported progress with the FDA on a potential accelerated approval path for BEAM‑302 and plans to file a Biologics License Application (BLA) for risto‑cel as early as the end of 2026.
Beam said it has reached alignment with the FDA on a potential accelerated approval pathway for BEAM‑302, using biomarker endpoints in alpha‑1 antitrypsin deficiency (AATD). The company plans to enroll about 50 additional patients at the optimal biologic dose as part of an expanded Phase 1/2 study.
Beam estimates it ended 2025 with roughly $1.25 billion in cash, cash equivalents and marketable securities, including $255.1 million from Bristol‑Myers Squibb Co (NYSE:BMY)'s acquisition of Orbital Therapeutics.
The company expects its cash runway to support operations and capital needs into 2029, covering the anticipated launch of risto‑cel and the pivotal development program for BEAM‑302.
Beam Stock Darts Toward Key Levels
Beam Therapeutics is trading 24.3% above its 20-day simple moving average (SMA) and 40.7% above its 100-day SMA, demonstrating strong short-term momentum.
The RSI is at 52.32, which is considered neutral territory, indicating that the stock is neither overbought nor oversold. Meanwhile, MACD is below its signal line, suggesting bearish pressure on the stock.
Key resistance is set at $35.50, which traders should monitor closely. A breakout above this level could signal a continuation of the current uptrend, while a failure to break through may lead to a consolidation phase.
Over the past 12 months, Beam Therapeutics has gained 32.97%, reflecting a solid longer-term trend. This performance indicates that the stock has been on a steady upward trajectory, reinforcing the bullish outlook.
BEAM Price Action: Beam Therapeutics shares were up 23.67% at $34.07 at the time of publication on Monday. The stock is trading near its 52-week high of $35.25, according to Benzinga Pro.
Image: Shutterstock
